ATNC05
Small molecule
ATNC05 is one of 18 small molecule programs targeting Facial Pain. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Facial Pain
#DrugCompanyPhaseTrials
1Aimovig
AmgenApproved
Lexapro
AbbVieApproved
Decadron
AAspen Global Incorporated
Approved
Kenalog
BBassett Healthcare
Approved
Marcaine
IInnocoll
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Robitussin
PfizerPhase 2
Xylocaine
MMEDRx USA, Inc.
Phase 2
Botox
RRevance Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ATNC05. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- AAllodynic Therapeutics, Inc